Deconstructing adaptive evolution of metastasis
Akronyymi
Adaptmet
Rahoitetun hankkeen kuvaus
Adaptmet aims to develop an advanced training program encompassing the multifaceted aspects of metastasis adaptation mechanisms, intending to equip budding researchers with the necessary skills to emerge as leaders in this field. A robust mentoring and training strategy, coupled with cutting-edge methodologies and a diverse range of complementary soft skills, are crucial to this endeavour. These skills are imparted through local and network-wide events, fostering seamless research progression, and nurturing successful career trajectories. Scientifically, Adaptmet addresses an unmet medical need by harnessing basic science to revolutionize drug development and, ultimately, enhance patient care. Specifically, scientific work packages (WPs) have been designed to approach metastasis from various functional perspectives. In order to metastasize, cancer cells must adeptly coordinate diverse cellular functions (Cell Fate - WP1). Additionally, understanding the intricate interactions between metastatic cells, the host immune system, and tissue stroma is pivotal (Environment – WP2). Crucial aspects such as the kinetics of metastasis and the mechanisms governing latency, particularly, remain inadequately understood (Latency – WP3). Clarifying this complexity, unravelling mechanisms underlying therapy failure, and identifying expansion pathways are central to defining novel therapeutic targets (Expansion – WP4). In essence, Adaptmet stands at the intersection of a rapidly evolving multidisciplinary domain, amalgamating distinct fields that often face challenges in mutual communication. The success of Adaptmet hinges upon robust partnerships, open exchange of ideas, state-of-the-art methodologies and equipment, and the exploitation of synergistic opportunities among network members. This collaboration spans diverse perspectives, bridging gaps between different disciplines, thereby breaking down barriers and fostering interdisciplinary cohesion.
Näytä enemmänAloitusvuosi
2025
Päättymisvuosi
2029
Myönnetty rahoitus
CANCER STATE THERAPEUTICS (BE)
262 620 €
Participant
GR ESPANOL DE ESTUDIO Y TRATAMIENTODE INTENSIFIC. Y OTRAS ESTRATEG.EXPERIMENT. EN TUMORES SOLIDOS - GRUPO SOLTI (ES)
Participant
LUNDS UNIVERSITET (SE)
293 709.6 €
Participant
Saso Kocevar (DE)
Participant
SCIENSEED SL (ES)
Participant
FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS (ES)
251 971.2 €
Participant
BOEHRINGER INGELHEIM RCV GMBH & CO KG (AT)
270 331.2 €
Participant
INTOMICS AS (DK)
301 788 €
Participant
THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (UK)
Participant
FUNDACIO CLINIC PER A LA RECERCA BIOMEDICA (ES)
251 971.2 €
Participant
FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA) (ES)
503 942.4 €
Coordinator
FUNDACIO INSTITUT MAR D INVESTIGACIONS MEDIQUES IMIM (ES)
Participant
UNIVERSITE DE LAUSANNE (CH)
Participant
UNIVERSITAT WIEN (AT)
Participant
UNIVERSITAT BASEL (CH)
Participant
FORSCHUNGSINSTITUT FUR MOLEKULARE PATHOLOGIE GESELLSCHAFT MBH (AT)
270 331.2 €
Participant
STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS (NL)
274 370.4 €
Participant
UNIVERSITE LIBRE DE BRUXELLES (BE)
262 620 €
Participant
UNIVERSITAT DE BARCELONA (ES)
Participant
DANMARKS TEKNISKE UNIVERSITET (DK)
Participant
ACADEMISCH ZIEKENHUIS LEIDEN (NL)
Participant
Myönnetty summa
3 516 631 €
Rahoittaja
Euroopan unioni
Rahoitusmuoto
HORIZON TMA MSCA Doctoral Networks
Puiteohjelma
Horizon Europe (HORIZON)
Haku
Ohjelman osa
Marie Skłodowska-Curie Actions (MSCA) (11677Aihe
MSCA Doctoral Networks 2023 (HORIZON-MSCA-2023-DN-01-01Haun tunniste
HORIZON-MSCA-2023-DN-01 Muut tiedot
Rahoituspäätöksen numero
101169223